Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Deep Track Capital, LP
Form 13F · Q2 2026

Deep Track Capital, LP

CIK 1856083Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$6.9B
Reported book value
67
Positions
12
Quarters on record
Top 50
Positions

Deep Track Capital, LP — holdings

Top 50 positions of 67, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1GH Guardant Health Inc3.4M+1.6%$509M7.4%
2IMVT Immunovant Inc9.3M−19.0%$360M5.2%
3GPCR Structure Therapeutics Inc4.7M+10.8%$254M3.7%
4PCVX Vaxcyte Inc4.3M+0.0%$250M3.6%
5ALNY Alnylam Pharmaceuticals Inc825,000—$248M3.6%
6MANE Veradermics Inc2.0M+300.0%$246M3.6%
7TARS Tarsus Pharmaceuticals Inc3.7M+1.9%$231M3.4%
8NUVALENT INC Nuvalent Inc1.8M+29.6%$220M3.2%
9ALKS Alkermes Plc4.0M+11.4%$210M3.1%
10OCUL Ocular Therapeutix Inc19.7M+0.0%$193M2.8%
11BMRN Biomarin Pharmaceutical Inc3.3M+187.6%$189M2.8%
12NRIX Nurix Therapeutics Inc7.7M+21.9%$188M2.7%
13ORKA Oruka Therapeutics Inc1.9M−5.3%$183M2.7%
14ALMS Alumis Inc6.3M−6.3%$179M2.6%
15IONS Ionis Pharmaceuticals Inc2.2M+12.8%$174M2.5%
16CMPS Compass Pathways Plc12.2M+0.0%$172M2.5%
17VERA Vera Therapeutics Inc4.0M−2.6%$172M2.5%
18AXSM Axsome Therapeutics Inc.700,000−36.4%$171M2.5%
19GMAB Genmab A/S5.7M+54.2%$155M2.3%
20MLTX Moonlake Immunotherapeutics7.0M+9.2%$136M2.0%
21COAG Hemab Therapeutics Hldgs Inc3.6M—$132M1.9%
22TNGX Tango Therapeutics Inc4.2M+52.7%$131M1.9%
23DFTX Definium Therapeutics Inc2.8M−8.3%$129M1.9%
24GRAL Grail Inc1.8M+6.5%$125M1.8%
25BCAX Bicara Therapeutics Inc4.1M+0.9%$122M1.8%
26MAZE Maze Therapeutics Inc3.7M+7.3%$111M1.6%
27CLDX Celldex Therapeutics Inc New2.9M+128.9%$109M1.6%
28LBRX Lb Pharmaceuticals Inc3.4M+0.0%$109M1.6%
29MBX Mbx Biosciences Inc1.7M−37.2%$96M1.4%
30GHRS Gh Research Plc3.3M—$90M1.3%
31COGT Cogent Biosciences Inc2.0M+100.0%$77M1.1%
32ATAIBECKLEY INC Ataibeckley Inc14.4M+20.1%$76M1.1%
33UTHR United Therapeutics Corp Del123,616—$67M1.0%
34AVTX Avalo Therapeutics Inc3.6M—$67M1.0%
35VRDN Viridian Therapeutics Inc3.6M+157.7%$66M1.0%
36CYTK Cytokinetics Inc700,000−49.1%$60M0.9%
37ALT Altimmune Inc19.2M—$59M0.9%
38PSNL Personalis Inc4.0M+33.3%$54M0.8%
39ACRS Aclaris Therapeutics Inc9.3M+0.0%$49M0.7%
40CRMD Cormedix Inc6.3M+0.0%$49M0.7%
41WGS Genedx Holdings Corp700,000—$48M0.7%
42HROW Harrow Inc969,000—$41M0.6%
43CRVS Corvus Pharmaceuticals Inc2.5M+0.0%$37M0.5%
44SLDB Solid Biosciences Inc3.6M+0.0%$36M0.5%
45BEAM Beam Therapeutics Inc1.0M+21.8%$34M0.5%
46DYN Dyne Therapeutics Inc1.5M−25.0%$33M0.5%
47IMMX Immix Biopharma Inc2.8M—$29M0.4%
48XFOR X4 Pharmaceuticals Inc5.9M−7.3%$27M0.4%
49STTK Shattuck Labs Inc3.7M—$26M0.4%
50MNKD Mannkind Corp6.0M—$26M0.4%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.